var data={"title":"Cefotaxime: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefotaxime: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5840?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefotaxime-drug-information\" class=\"drug drug_general\">see &quot;Cefotaxime: Drug information&quot;</a> and <a href=\"topic.htm?path=cefotaxime-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefotaxime: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147493\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Claforan in D5W [DSC];</li>\n      <li>Claforan [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147494\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cefotaxime Sodium For Injection;</li>\n      <li>Claforan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045979\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442224\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b> IM, IV (<i>Red Book </i>[AAP 2015]):</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Body</p>\n            <p style=\"text-indent:0em;\">Weight</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Postnatal</p>\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose</p></th></tr></thead>\n      <tbody valign=\"middle\">\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 to 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 to 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg/dose every 8 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gonococcal infections, disseminated (including sepsis, arthritis, and meningitis)/scalp abscess:</b> IM, IV: 25 mg/kg/dose every 12 hours for 7 days; therapy should be extended to 10 to 14 days if meningitis is documented (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis</b> (Tunkel 2004): IV: <b>Note:</b> Treat for a minimum of 21 days; use smaller doses and longer intervals for neonates &lt;2 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &le;7 days and &ge;2 kg: 100 to 150 mg/kg/<b>day</b> divided every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">PNA &gt;7 days and &ge;2 kg: 150 to 200 mg/kg/<b>day</b> divided every 6 to 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045972\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefotaxime-drug-information\" class=\"drug drug_general\">see &quot;Cefotaxime: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Infants, Children, and Adolescents: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">AAP recommendations (<i>Red Book </i>[AAP 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate infection: 50 to 180 mg/kg/<b>day</b> in divided doses every 6 to 8 hours; maximum daily dose: 6 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe infection: 200 to 225 mg/kg/<b>day</b> in divided doses every 4 to 6 hours; up to 300 mg/kg/<b>day</b> has been used for meningitis; maximum daily dose: 12 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;50 kg: 50 to 180 mg/kg/<b>day</b> divided every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Uncomplicated infections: IM, IV: 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate to severe infections: IM, IV: 1,000 to 2,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Life-threatening infections: IV: 2,000 mg every 4 hours, maximum daily dose: 12 <b>g/day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute bacterial rhinosinusitis, severe infection requiring hospitalization:</b> Children and Adolescents: IV: 100 to 200 mg/kg/<b>day</b> divided every 6 hours for 10 to 14 days; maximum dose: 2,000 mg (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment</b>: Children and Adolescents: IV: 200 mg/kg/<b>day</b> in divided doses every 6 hours; maximum daily dose: 12 <b>g</b>/<b>day</b>; treat for at least 4 to 6 weeks; longer durations may be necessary; may use in combination with gentamicin for some organisms (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Enteric bacterial infections, empiric treatment (HIV-exposed/-positive):</b> Adolescents: IV: 1,000 mg every 8 hours (HHS [OI adult] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonorrhea, disseminated infections (including arthritis and arthritis-dermatitis syndrome)</b> <b>(as an alternative to ceftriaxone)</b> (CDC [Workowski 2015]): Adolescents: IV: 1,000 mg every 8 hours in combination with azithromycin for a total duration of at least 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum dose: 2,000 mg; use in combination with metronidazole (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme disease, cardiac or CNS manifestations or recurrent arthritis:</b> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/<b>day</b> in divided doses every 6 to 8 hours for 14 to 28 days; maximum daily dose: 6 <b>g/day</b> (Halperin 2007; <i>Red Book</i> [AAP 2015]; Wormser 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis:</b> Infants, Children, and Adolescents: IV: 225 to 300 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum dose: 2,000 mg; use in combination with vancomycin for empiric coverage (Tunkel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis)</b> (ISPD [Warady 2012]): Infants, Children, and Adolescents: Intraperitoneal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent: 30 mg/kg/dose every 24 hours in the long dwell</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous: Loading dose: 500 mg per liter of dialysate; maintenance dose: 250 mg per liter; <b>Note:</b> 125 mg/liter has also been recommended as a maintenance dose (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bacterial pneumonia (HIV-exposed/-positive):</i> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum dose: 2,000 mg/dose (HHS [OI adult 2015]; HHS [OI pediatric 2013]); consider more frequent dosing for severe or life-threatening infections (every 4 to 6 hours) (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Community-acquired pneumonia (CAP):</i> Infants &gt;3 months, Children, and Adolescents: IV: 50 mg/kg/dose every 8 hours; maximum dose: 2,000 mg; <b>Note:</b> May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out (IDSA/PIDS [Bradley 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Salmonellosis (HIV-exposed/-positive):</b> Adolescents: IV: 1,000 mg every 8 hours (HHS [OI adult] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue infections, necrotizing</b>: Infants, Children, and Adolescents: IV: 50 mg/kg/dose every 6 hours in combination with metronidazole or clindamycin; maximum dose: 2,000 mg/dose. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 50 mg/kg within 60 minutes prior to the procedure; may repeat in 3 hours if procedure is lengthy or if there is excessive blood loss; maximum dose: 1,000 mg (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection:</b> Infants and Children 2 to 24 months: IM, IV: 150 mg/kg/<b>day</b> divided every 6 to 8 hours (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Usual dosage range:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uncomplicated infections: IM, IV: 1,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe infections: IM, IV: 1,000 to 2,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Life-threatening infections: IV: 2,000 mg every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial enteric infections in HIV-infected patients (empiric treatment):</b> IV: 1,000 mg every 8 hours (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bite wounds (animal):</b> IV: 1,000 to 2,000 mg every 6 to 8 hours in combination with clindamycin or metronidazole for anaerobic coverage (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Caesarean section:</b> IM, IV: 1,000 mg IV as soon as the umbilical cord is clamped, then 1,000 mg IV or IM at 6 and 12 hours after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonorrhea, uncomplicated infection of the cervix, urethra, or rectum: Note:</b> CDC STD guidelines do not recommend cefotaxime as a treatment option for uncomplicated gonorrhea; ceftriaxone is the preferred cephalosporin (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated gonorrhea of the cervix or urethra (males or females) or of the rectum (females):</i> Manufacturer's labeling: IM: 500 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Uncomplicated gonorrhea of the rectum (males):</i> Manufacturer's labeling: IM: 1,000 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonorrhea, disseminated</b> <b>infections (arthritis and arthritis-dermatitis syndrome)</b>: IV: 1,000 mg every 8 hours in combination with azithromycin. Continue for 24 to 48 hours after improvement begins, then switch to oral therapy guided by antimicrobial susceptibility testing. Total duration of therapy at least 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sepsis:</b> IV: 2,000 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Polymicrobial infection:</i> IV: 2,000 mg every 6 hours in combination with metronidazole or clindamycin for empiric therapy. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Necrotizing infection due to Vibrio vulnificus:</i> IV: 2,000 mg every 8 hours in combination with doxycycline. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 100 to 200 mg/kg/<b>day</b> divided every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 35 to 70 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: 35 to 70 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 35 to 70 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): 35 to 70 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: <b>Note:</b> Renal function may be estimated using Cockcroft-Gault formula for dosage adjustment purposes.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;20 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment required</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">CrCl &lt;20 mL/minute/1.73 m<sup>2</sup>: Dose should be decreased by 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate Dosing: The following dosage adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &gt;50 mL/minute: Administer every 6 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 50 mL/minute: Administer every 6 to 12 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute: Administer every 24 hours <b>or</b> decrease the dose by 50% (and administer at usual intervals) (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD): 1,000 to 2,000 mg every 24 hours (on dialysis days, administer after hemodialysis). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions (Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): 1,000 mg every 24 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CVVH: 1,000 to 2,000 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CVVHD: 1,000 to 2,000 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CVVHDF: 1,000 to 2,000 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147472\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claforan in D5W: 1 g/50 mL (50 mL [DSC]); 2 g/50 mL (50 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claforan: 500 mg (1 ea [DSC]); 1 g (1 ea [DSC]); 2 g (1 ea [DSC]); 10 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea); 10 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Claforan: 1 g (1 ea [DSC]); 2 g (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147456\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045982\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus. Doses of 2,000 mg should be divided and administered at two different sites.   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IVP: May be administered over 3 to 5 minutes; avoid rapid injection (&lt;1 minute) due to association with arrhythmias </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent infusion: Infuse over 15 to 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24956504\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials below 30&deg;C (86&deg;F).  Protect from light. Reconstituted solution is stable for 12 to 24 hours at room temperature, 7 to 10 days when refrigerated, for 13 weeks when frozen. For IV infusion in NS or D<sub>5</sub>W, solution is stable for 24 hours at room temperature, 5 days when refrigerated, or 13 weeks when frozen in Viaflex plastic containers. Thawed solutions of frozen premixed bags are stable for 24 hours at room temperature or 10 days when refrigerated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045981\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible lower respiratory tract, skin and skin structure, bone and joint, intra-abdominal, genitourinary tract, and gynecologic infections, bacteremia/septicemia and documented or suspected central nervous system infections (eg, meningitis, ventriculitis) (FDA approved in all ages); prevention of postoperative surgical site infection in contaminated or potentially contaminated surgical procedures [eg, gastrointestinal and genitourinary tract surgeries and hysterectomy (abdominal or vaginal)] and caesarian section (FDA approved in all ages); has also been used for the treatment of peritonitis in patients with peritoneal catheters</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147549\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cefotaxime may be confused with cefOXitin, cefuroxime</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Spectrocef [Italy] may be confused with Spectracef brand name for cefditoren [US, Great Britain, Mexico, Portugal, Spain]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147546\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Colitis, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Induration at injection site (IM), inflammation at injection site (IV), pain at injection site (IM), tenderness at injection site (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Acute generalized exanthematous pustulosis, acute renal failure, agranulocytosis, anaphylaxis, bone marrow failure, brain disease, candidiasis, cardiac arrhythmia (after rapid IV injection via central catheter), cholestasis, <i>Clostridium difficile</i> associated diarrhea, erythema multiforme, granulocytopenia, hemolytic anemia, hepatitis, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, injection site phlebitis, interstitial nephritis, jaundice, leukopenia, neutropenia, pancytopenia, positive direct Coombs test, pseudomembranous colitis, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, vaginitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147479\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefotaxime, any component of the formulation, or other cephalosporins</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147460\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmia: A potentially life-threatening arrhythmia has been reported in patients who received a rapid (&lt;1 minute) bolus injection via central venous catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Granulocytopenia: Granulocytopenia and more rarely agranulocytosis may develop during prolonged treatment (&gt;10 days).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tissue inflammation: Minimize tissue inflammation by changing infusion sites when needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Colitis: Use with caution in patients with a history of colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\tDrug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298990\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147465\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13129&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cefotaxime. Management: Avoid cefotaxime doses greater than 6 g/day with concurrent probenecid.  Any patients receiving this combination should be monitored closely for evidence of cefotaxime toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147468\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951413\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Cefotaxime crosses the human placenta and can be found in fetal tissue. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins. During pregnancy, peak cefotaxime serum concentrations are decreased and the serum half-life is shorter. Cefotaxime is approved for use in women undergoing cesarean section (consult current guidelines for appropriate use).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045978\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for signs and symptoms of anaphylaxis during first dose; monitor infusion site for extravasation; with prolonged therapy, monitor renal, hepatic, and hematologic function periodically; number and type of stools/day for diarrhea </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147459\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Cefotaxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria. <i>Enterococcus</i> species may be intrinsically resistant to cefotaxime. Most extended-spectrum beta-lactamase (ESBL)-producing and carbapenemase-producing isolates are resistant to cefotaxime. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147478\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely to body tissues and fluids including aqueous humor, ascitic and prostatic fluids, bone; penetrates CSF best when meninges are inflamed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 31% to 50% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Partially hepatic to active metabolite, desacetylcefotaxime </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cefotaxime: Infants &le;1500 g: 4.6 hours; Infants &gt;1500 g: 3.4 hours; Children: 1.5 hours; Adults: 1 to 1.5 hours; prolonged with renal and/or hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Desacetylcefotaxime: 1.3 to 1.9 hours; prolonged with renal impairment (Ings 1982) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: Within 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~60% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323047\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cefotaxime Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $2.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $6.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $32.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $1.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147483\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benaxima (MX);</li>\n      <li>Biosint (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Biotax (IN);</li>\n      <li>Cefacolin (AR);</li>\n      <li>Cefalekol (HU);</li>\n      <li>Cefirad (KR);</li>\n      <li>Cefocam (PY);</li>\n      <li>Cefot (BD);</li>\n      <li>Cefotaksim (HR);</li>\n      <li>Cefotax (AE, BH, CY, EG, IQ, IR, JO, JP, KW, LB, LY, OM, RO, SA, SY, YE);</li>\n      <li>Cefotaxim (DE, NO);</li>\n      <li>Cefotrial (PE);</li>\n      <li>Cefox (PH);</li>\n      <li>Cefoxim (KR);</li>\n      <li>Cefpiran (KR);</li>\n      <li>Ceftax (AE, BH, JO, QA, SA);</li>\n      <li>Cetax (TW);</li>\n      <li>Clacef (ID);</li>\n      <li>Cladex (PH);</li>\n      <li>Claforan (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CR, CY, DK, DO, EC, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PH, PK, PY, QA, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Clafotax (BH, JO, KW, QA, SA);</li>\n      <li>Claraxim (TH);</li>\n      <li>Clatax (ID);</li>\n      <li>Clavox (TW);</li>\n      <li>Diabec (BD);</li>\n      <li>Efotax (ID);</li>\n      <li>Fahotsef (UA);</li>\n      <li>Fot-Amsa (MX);</li>\n      <li>Fotax (BD);</li>\n      <li>Fotexina (CO, CR, DO, EC, GT, HN, MX, NI, PA, SV);</li>\n      <li>Glocef (ID);</li>\n      <li>Gloryfen (LB, MT);</li>\n      <li>Grifotaxima (CL);</li>\n      <li>Haxim (PH);</li>\n      <li>Kalfoxim (ID);</li>\n      <li>Lancef (ID);</li>\n      <li>Lapixime (ID);</li>\n      <li>Letynol (MT);</li>\n      <li>Loraksym (UA);</li>\n      <li>Lyforan (IN);</li>\n      <li>Makrocef (HR);</li>\n      <li>Molelant (GR);</li>\n      <li>Necaxime (TH);</li>\n      <li>Newtaxime (KR);</li>\n      <li>Novatax (LK);</li>\n      <li>Omnatax (IN);</li>\n      <li>Oritaxim (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Oritaxim-1000 (LK);</li>\n      <li>Pantaxin (PH);</li>\n      <li>Primocef (AE);</li>\n      <li>Procefa (ID);</li>\n      <li>Racotax (LK);</li>\n      <li>Ralopar (PT);</li>\n      <li>Reftax (ZA);</li>\n      <li>Rekaxime (MY);</li>\n      <li>Saifulong (CN);</li>\n      <li>Sefotak (AE, BH, CY, CZ, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Soclaf (ID);</li>\n      <li>Spirosine (GR);</li>\n      <li>Stoparen (GR, LB);</li>\n      <li>Talcef (PE);</li>\n      <li>Taporin (MX);</li>\n      <li>Taxibiotic (VN);</li>\n      <li>Taxim (BD);</li>\n      <li>Taximax (ID);</li>\n      <li>Taxime (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Taximed (CZ);</li>\n      <li>Taximmed (VN);</li>\n      <li>Tebruxim (MX);</li>\n      <li>Tirdicef (ID);</li>\n      <li>Tirotax (MX, PL, QA);</li>\n      <li>Ultracef (UY);</li>\n      <li>Unitax (TW);</li>\n      <li>Valoran (EE, MT);</li>\n      <li>Viken (MX);</li>\n      <li>Xedin (MX);</li>\n      <li>Xendin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ximvex (PH);</li>\n      <li>Zariviz (IT);</li>\n      <li>Zefocent (PH);</li>\n      <li>Zefotax (PH);</li>\n      <li>Zentro (PH);</li>\n      <li>Zetax (ET)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. <i> Pediatrics</i>. 2011;128(3):595-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/21873693/pubmed\" target=\"_blank\" id=\"21873693\">21873693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association.  <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &quot;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&quot; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claforan injection (cefotaxime) [prescribing information]. Bridgewater, NJ: sanofi-aventiz U.S. LLC; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin JJ, Shapiro ED, Logigian E, et al, &ldquo;Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,&quot; <i>Neurology</i>, 2007, 69(1):91-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/17522387/pubmed\" target=\"_blank\" id=\"17522387\">17522387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. December 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed March 17, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. <i>Rev Infect Dis</i>. 1982;(4 Suppl):S379-391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/6294787/pubmed\" target=\"_blank\" id=\"6294787\">6294787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>,  2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spritzer R, Kamp HJ, Dzoljic G, et al, &ldquo;Five Years of Cefotaxime Use in a Neonatal Intensive Care Unit,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(2):92-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/2179846/pubmed\" target=\"_blank\" id=\"2179846\">2179846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, (32 Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137. Erratum in: <i>MMWR Recomm Rep</i>. 2015;64(33):924.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefotaxime-pediatric-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13129 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F147493\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F147494\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045979\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442224\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045972\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147472\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F147456\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045982\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F24956504\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045981\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F147549\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147546\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147479\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147460\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298990\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147465\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147468\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5951413\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045978\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147459\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F147478\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323047\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147483\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13129|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefotaxime-drug-information\" class=\"drug drug_general\">Cefotaxime: Drug information</a></li><li><a href=\"topic.htm?path=cefotaxime-patient-drug-information\" class=\"drug drug_patient\">Cefotaxime: Patient drug information</a></li></ul></div></div>","javascript":null}